{
  "id": 117713,
  "name": "PHRMA INC.",
  "slug": "phrma-inc",
  "state": "DC",
  "description": "Represents leading research-based pharmaceutical and biotechnology companies in the US",
  "totalSpending": 2025000,
  "filings": 28,
  "yearlySpending": [
    {
      "year": 2018,
      "income": 300000
    },
    {
      "year": 2019,
      "income": 275000
    },
    {
      "year": 2020,
      "income": 225000
    },
    {
      "year": 2021,
      "income": 300000
    },
    {
      "year": 2022,
      "income": 300000
    },
    {
      "year": 2023,
      "income": 300000
    },
    {
      "year": 2024,
      "income": 300000
    },
    {
      "year": 2025,
      "income": 25000
    }
  ],
  "firms": [
    "THE DUBERSTEIN GROUP INC."
  ],
  "lobbyists": [
    "BRIAN GRIFFIN",
    "ANNE BRADBURY",
    "DANIEL MEYER",
    "DAVID SCHIAPPA",
    "ANNE WALL",
    "KATHERINE KEATING",
    "BENJAMIN HOWARD",
    "ELIZABETH KELLEY"
  ],
  "issues": [
    "HCR",
    "BUD",
    "MMM",
    "TRD",
    null
  ],
  "sampleDescriptions": [
    "Drug Pricing",
    "Pay-Fors.\n\nMedicare Part D:\nHR 1625 (Royce) - Consolidated Appropriations Act, 2018\nHR 1892 (Larson) - Bipartisan Budget Act of 2018",
    "Medicare Part D:\nHR 1625 (Royce) - Consolidated Appropriations Act, 2018\nHR 1892 (Larson) - Bipartisan Budget Act of 2018\n\nPay-fors.",
    "Drug Pricing\n\nCREATES Act",
    "Medicare Part D:\nHR 1625 (Royce) - Consolidated Appropriations Act, 2018\nHR 1892 (Larson) - Bipartisan Budget Act of 2018\n\nDrug Pricing\n\nPay-fors.",
    "Drug Pricing.\n\nPay Fors",
    "Medicare Part D.",
    "Drug Pricing.\n\nCREATES Act.\n\nOpioids.",
    "Pay Fors.",
    "Drug Pricing.\n\nCREATES Act.\n\nOpioids legislation.",
    "Medicare Part D\n\nSix Protected Classes Rule",
    "Pay Fors",
    "Trade",
    "Medicare Part D",
    "Drug Pricing\n\nH.R.3 (Pallone) - Lower Drug Costs Now Act of 2019",
    "Drug Pricing\n\nIssues related to COVID-19: H.R.6201 - Families First Coronavirus Response Act; H.R.748 - CARES Act \n\nNotice of Benefit and Payment Parameters (NBPP) Letter to HHS",
    "Drug Pricing\n\nIssues related to COVID-19: H.R.748 - CARES Act \n\nH.R.1425 (Craig) - Patient Protection & Affordable Care Enhancement Act",
    "Drug Pricing\n\nIssues related to COVID-19: H.R.748 - CARES Act \n\nDrug pricing; most-favored nations rule",
    "Drug Pricing\n\n340B Program",
    "Issues related to Medicare Part D and the 6 protected classes"
  ],
  "years": [
    2018,
    2019,
    2020,
    2021,
    2022,
    2023,
    2024,
    2025
  ],
  "growthRate": -92,
  "trajectory": "declining",
  "yearsActive": 8,
  "avgAnnualSpending": 253125,
  "peakYear": 2018,
  "lobbyistCount": 8,
  "firmCount": 1,
  "issueCount": 4,
  "industry": "healthcare"
}